Sanofi, GSK Kick Off Phase 1/2 COVID-19 Vaccine Trial in the U.S.

Sanofi and GlaxoSmithKline (GSK) have launched a phase 1/2 trial of their COVID-19 vaccine candidate in the U.S.

The trial will compare the vaccine vs. a placebo in 440 healthy adults. It will study the vaccine’s safety and tolerability and its ability to induce an immune response. Data from the trial is expected by December, when the companies also plan to begin a phase 3 trial.

Sanofi and GSK plan to file for approval of the vaccine in the first half of 2021.